1/26
Vocabulary flashcards covering the basic considerations, monitoring, insulin preparations, and non-insulin medications for diabetes based on Chapter 48.
Type 1 Diabetes (T1D)
A form of diabetes accounting for approximately 5% of cases, characterized by autoimmune destruction of pancreatic beta cells, absolute insulin deficiency, and a mandatory requirement for insulin replacement.
Type 2 Diabetes (T2D)
The most prevalent form of diabetes, accounting for 90% to 95% of diagnosed cases, resulting from a combination of cellular insulin resistance and impaired insulin secretion.
Prediabetes
A metabolic state defined by an impaired fasting plasma glucose of 100 to 125mg/dL or an impaired 2-hour oral glucose tolerance test result of 140 to 199mg/dL, increasing the risk for T2D and cardiovascular disease.
Hemoglobin A1c
A standard blood test that measures the percentage of glycated hemoglobin to provide an index of average blood glucose control over the prior 2 to 3 months.
Estimated Average Glucose (eAG)
A value reported in mg/dL calculated from Hemoglobin A1c percentage using the formula eAG=28.7×A1c−46.7.
Self-Monitoring of Blood Glucose (SMBG)
The standard day-to-day blood glucose monitoring method using capillary blood, recommended for all patients receiving insulin to guide dosage adjustments.
Continuous Glucose Monitoring (CGM)
A monitoring technology using a worn sensor that measures interstitial glucose levels every 5 minutes for 10 to 14 days.
Short-Duration: Rapid-Acting Insulin
Insulin human analogs (lispro, aspart, glulisine) characterized by a rapid onset (10 to 30minutes) and short duration (3 to 6hours), administered subcutaneously right before meals to control postprandial hyperglycemia.
Regular Insulin
Unmodified short-acting human insulin (Humulin R, Novolin R) administered subcutaneously 30minutes before meals or intravenously for glycemic management in emergency and inpatient settings.
Neutral Protamine Hagedorn (NPH) Insulin
An intermediate-duration insulin created by conjugating regular insulin with protamine to delay absorption, administered subcutaneously twice daily to provide basal glycemic control between meals and overnight.
Insulin Glargine (U-100)
A long-acting human insulin analog that forms microprecipitates upon subcutaneous injection to steadily release insulin over up to 24hours without a sharp peak.
Insulin Degludec
An ultra-long-acting human insulin analog available in U-100 and U-200 concentrations that provides steady, peakless basal glycemic control for in excess of 24hours.
Metformin
The preferred first-line biguanide oral antidiabetic drug that lowers blood glucose by inhibiting hepatic glucose production, reducing intestinal glucose absorption, and increasing tissue insulin sensitivity.
Lactic Acidosis
A rare, potentially fatal complication of metformin accumulation caused by inhibition of mitochondrial lactic acid oxidation, presenting with hyperventilation, myalgia, malaise, and unusual somnolence.
Sulfonylureas
A class of oral antidiabetic secretagogues (glipizide, glyburide, glimepiride) that stimulate pancreatic beta-cell insulin release by blocking ATP-sensitive potassium channels.
Meglitinides (Glinides)
Short-acting oral insulin secretagogues (repaglinide, nateglinide) taken within 30minutes before meals to facilitate calcium influx and stimulate rapid pancreatic insulin release.
Thiazolidinediones (Glitazones / TZDs)
Oral antidiabetic agents (pioglitazone) that activate nuclear PPAR-gamma receptors to reduce insulin resistance and increase glucose uptake in skeletal muscle and adipose tissue.
Alpha-Glucosidase Inhibitors
Oral drugs (acarbose, miglitol) that inhibit brush-border alpha-glucosidase in the small intestine, slowing complex carbohydrate digestion to decrease postprandial glucose spikes.
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Gliptins)
Oral drugs (sitagliptin, saxagliptin, linagliptin, alogliptin) that inhibit DPP-4 to prevent incretin degradation, boosting glucose-dependent insulin release and suppressing glucagon.
Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors
Oral antidiabetic drugs (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, bexagliflozin) that block glucose reabsorption in renal tubules, increasing urinary glucose excretion.
GLP-1 Receptor Agonists (Incretin Mimetics)
Injectable drugs (exenatide, liraglutide, dulaglutide, semaglutide) that activate GLP-1 receptors to slow gastric emptying, stimulate glucose-dependent insulin release, suppress glucagon, and reduce appetite.
Tirzepatide
A dual GIP and GLP-1 receptor agonist injected subcutaneously once weekly that enhances insulin release, decreases hepatic glucose output, increases satiety, and promotes significant weight loss.
Pramlintide
A synthetic amylin mimetic injected subcutaneously immediately before major meals in T1D or T2D to delay gastric emptying and suppress glucagon secretion.
Diabetic Ketoacidosis (DKA)
A severe, rapid-onset hyperglycemic crisis seen mainly in T1D, characterized by hyperglycemia (>250mg/dL), ketoacid production, metabolic acidosis, hemoconcentration, and fruity-smelling breath.
Hyperosmolar Hyperglycemic State (HHS)
A gradual-onset hyperglycemic crisis occurring mainly in T2D, characterized by extreme hyperglycemia (>600mg/dL), severe dehydration, and high plasma osmolality (>320mOsm) without ketoacidosis.
Glucagon
A pancreatic alpha-cell polypeptide hormone administered parenterally or intranasally to reverse severe hypoglycemia by stimulating hepatic glycogenolysis and gluconeogenesis.
Polycystic Ovary Syndrome (PCOS)
An endocrine-metabolic disorder in females characterized by androgen excess and insulin resistance, which can be managed off-label with metformin to improve ovulation and insulin sensitivity.